Third Harmonic Bio Inc.

NASDAQ THRD

Download Data

Third Harmonic Bio Inc. Asset Turnover Ratio 5 year CAGR for the quarter ending March 31, 2024

Third Harmonic Bio Inc. Asset Turnover Ratio 5 year CAGR is NA for the quarter ending March 31, 2024. The asset turnover ratio measures a company's efficiency in utilizing its assets to generate revenue. It is calculated by dividing the company's revenue by the average of its total assets and total non-current assets. This ratio indicates how effectively a company generates sales from its asset base. A higher ratio implies better asset utilization and revenue generation, while a lower ratio may suggest underutilization of assets or inefficient operations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Third Harmonic Bio Inc. Asset Turnover Ratio for the quarter ending March 31, 2023 was 0.00.
NASDAQ: THRD

Third Harmonic Bio Inc.

CEO Ms. Natalie C. Holles
IPO Date Sept. 14, 2022
Location United States
Headquarters 300 Technology Square, Cambridge, MA, United States, 02139
Employees 31
Sector Healthcare
Industry Biotechnology
Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Similar companies

NXTC

NextCure  Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

RLYB

Rallybio Corp

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email